Is TB-500 Legal in Texas?
HealthRX.com
Federally, TB-500 is unapproved and on no compounding list
See the public record for TB-500
At a glance
- Rules covered / federal rules for state-licensed pharmacies and physicians [4]
- FDA approval / none, in any country FDA checked [1]
- What it is / a 7-amino-acid fragment of thymosin beta-4, not the full protein [1]
- List for state-licensed pharmacies and physicians / in none of the three interim-policy categories [2][4]
- List for outsourcing facilities / not listed [3]
- Advisory committee / voted in favour on 23 July 2026; advice only [7][5]
- HHS draft policy / non-binding enforcement discretion, TB-500 acetate injections [5][6]
- Sport / WADA section S2.3, prohibited at all times [8][9]
Which rules apply to compounding TB-500 in Texas?
FDA's compounding framework applies to state-licensed pharmacies and physicians [4]. This page covers that federal position: approval status, the compounding lists and the draft enforcement-policy. It does not address Texas-specific rules.
Questions worth asking
Is TB-500 an approved drug?
No. FDA's July 2026 review found no USP or National Formulary monograph for TB-500, no FDA-approved drug containing it, no entry in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorised by the European Medicines Agency [1].
TB-500 is not thymosin beta-4 either: it is a synthetic, N-acetylated 7-amino-acid fragment (residues 17 to 23) of the 43-amino-acid protein, molecular weight about 889 g/mol, and FDA found several salts and derivatives sold under the same name [1].
What the federal compounding rules say
A state-licensed pharmacy or physician may use a bulk substance only if it has a USP or NF monograph, is a component of an approved drug, or appears on FDA's list for state-licensed pharmacies and physicians [4]. TB-500 meets none of those, sits in none of the three interim-policy categories, and is absent from FDA's list for outsourcing facilities [1][2][3][4].
FDA found no study in which TB-500 was given to a person, and none of the three papers the nominator cited involved TB-500 in humans [1]. FDA staff proposed in July 2026 that neither TB-500 free base nor TB-500 acetate be added to the bulks list, citing unclear historical use, no evidence of effectiveness for the wound-healing use FDA evaluated, and immunogenicity risk for injection [1]. The Pharmacy Compounding Advisory Committee voted in favour of adding it on 23 July 2026, advice only, and TB-500 is not on the list [7][5].
What the October 2026 HHS draft policy does
A draft HHS enforcement-discretion policy names TB-500 among six peptides, covering TB-500 acetate given by subcutaneous or intramuscular injection [5][6]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it when its conditions are met, such as a single active ingredient and a patient-specific prescription [5][6]. The notice states it 'does not establish any rights for any person and is not binding on HHS or the public' [5]. It is not an approval and does not put TB-500 on any list [5].
What is known about buying it and its safety
TB-500 is sold online as a 'research use only' injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157, and FDA found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1].
On safety, FDA's safety-risk page carries TB-500 in the 'nominated but withdrawn' table, for substances previously in category 2 whose nominators withdrew them. That placement was not a finding that TB-500 is safe. FDA cited no human exposure data on drug products containing the fragment and immunogenicity risk from aggregation and peptide-related impurities in injectable peptides [10]. FDA's adverse-event database search through 26 March 2025 returned no TB-500 reports, and it found no published case reports and no human pharmacokinetic data [1]. There is no approved dose and no human dosing study [1].
WADA names 'Thymosin-beta4 and its derivatives e.g. TB-500' in section S2.3 and prohibits it at all times, in and out of competition; it appears on the 2026 and 2027 Lists [8][9].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is TB-500 legal in Texas?
Does the HHS draft policy make TB-500 legal?
Is TB-500 banned in sport?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Is TB-500 FDA?
No. TB-500 is not an FDA-approved drug. FDA's July 2026 review found no USP or National Formulary monograph for it and no FDA-approved drug containing it, and it is not on FDA's compounding bulks lists. TB-500 is also not thymosin beta-4; it is a synthetic 7-amino-acid fragment of that 43-amino-acid protein.
Is TB-500 legal?
Federally, TB-500 cannot be compounded by state-licensed pharmacies or physicians under the usual rules, because it is not an approved drug and is on none of FDA's compounding lists. A non-binding draft HHS policy describes enforcement discretion for TB-500 acetate injections when specific conditions are met, but the notice says it establishes no rights. Texas-specific rules are not covered.
References
Show all 10 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- Official web page.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.